Benefiting From the...
Health Care: Drugs
Hyperion Therapeutics Inc (HPTX: NASDAQ)
$20.37 -0.43 | -2.07%
05/22/13 - 04:00 PM ET
Company Income Statement
| Dec 2012 | Dec 2011 | |||
| Sales | 0.00 | 0.00 | ||
| Cost of Sales | 0.00 | 0.00 | ||
| Gross Operating Profit | 0.00 | 0.00 | ||
| Selling, General, and Administrative Expenses | 11.49M | 8.92M | ||
| Research & Development | 17.05M | 17.24M | ||
| Operating Income before D & A (EBITDA) | -28.53M | -26.16M | ||
| Depreciation & Amortization | 1.40M | 1.63M | ||
| Interest Income | 12.00K | 28.00K | ||
| Other Income - Net | -39.00K | -731.00K | ||
| Special Income / Charges | 0.00 | 0.00 | ||
| Total Income Before Interest Expenses (EBIT) | -29.96M | -28.49M | ||
| Interest Expense | 3.70M | 2.55M | ||
| Pre-Tax Income | -33.66M | -31.05M | ||
| Income Taxes | 0.00 | 0.00 | ||
| Minority Interest | 0.00 | 0.00 | ||
| Net Income From Continuing Operations | -32.26M | -29.42M | ||
| Net Income From Discontinued Operations | 0.00 | 0.00 | ||
| Net Income From Total Operations | -32.26M | -29.42M | ||
| Extraordinary Income/Losses | 0.00 | 0.00 | ||
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | ||
| Income From Tax Loss Carryforward | 0.00 | 0.00 | ||
| Other Gains / Losses | 0.00 | 0.00 | ||
| Total Net Income | -32.26M | -29.42M | ||
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-32.26M | -29.42M | ||
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -32.26M | -29.42M | ||
| Basic EPS from Continuing Ops. | -4.45 | -2.98 | ||
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | ||
| Basic EPS from Total Operations | -4.45 | -2.98 | ||
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | ||
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | ||
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | ||
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | ||
| Basic EPS, Total | -4.45 | -2.98 | ||
| Basic Normalized Net Income/Share | -4.45 | -2.98 | ||
| EPS fr Continuing Ops. | -4.45 | -2.98 | ||
| EPS fr Discontinued Ops | 0.00 | 0.00 | ||
| EPS fr Total Ops. | -4.45 | -2.98 | ||
| EPS fr Extraord. Inc. | 0.00 | 0.00 | ||
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | ||
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | ||
| EPS fr Other Gains (L) | 0.00 | 0.00 | ||
| EPS, Total | -4.45 | -2.98 | ||
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-4.45 | -2.98 | ||
| Dividends Paid per Share | 0.00 | 0.00 | ||
Portfolios with HPTX
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
Latest HPTX Headlines from TheStreet
- Hyperion Therapeutics Added To NASDAQ Biotechnology Index (NBI) 05.16.13 | 04:05 pm
- Hyperion Therapeutics Announces First Quarter 2013 Operating Results 05.09.13 | 04:05 pm
- Hyperion Therapeutics To Report First Quarter 2013 Financial Results After Market On May 9, 2013 05.06.13 | 06:05 pm
- Hyperion Therapeutics Receives Orphan Drug Exclusivity From FDA 05.02.13 | 09:05 am
- Hyperion Therapeutics Exercises Option To Acquire Rights To BUPHENYL(R) And AMMONUL(R) 05.02.13 | 09:05 am
- Hyperion Therapeutics Becomes Oversold (HPTX) 05.01.13 | 12:05 pm
- Hyperion Therapeutics To Present At Needham's 12th Annual Healthcare Conference 04.25.13 | 04:04 pm
- Hyperion Therapeutics Issued Key Patent Pertaining To Use Of Fasting Ammonia 04.16.13 | 04:04 pm
- Hyperion Therapeutics Completes Follow-On Offering And Announces Exercise Of Underwriters' Over-Allotment Option 03.13.13 | 04:03 pm
- Hyperion Therapeutics Announces Pricing Of Follow-On Offering 03.08.13 | 09:03 am
Press Releases for HPTX
- Hyperion Therapeutics Completes Initial Public Offering And Announces Exercise Of Underwriters’ Over-Allotment Option - Business Wire 07.31.12 | 04:07 pm
- Hyperion Therapeutics Announces Pricing Of Initial Public Offering - Business Wire 07.26.12 | 08:07 am
Partner Headlines for HPTX
